Several analysts have recently updated their ratings and price targets for Retension Pharmaceuticals (NASDAQ: RTSN):
- 11/14/2026 – Retension Pharmaceuticals was upgraded by Wall Street Zen to “hold”.
- 11/4/2026 – Retension Pharmaceuticals is now covered by Zacks Research. They set a “hold” rating on the stock.
- 11/3/2026 – Retension Pharmaceuticals is now covered by Leerink Partners. They set a “strong-buy” rating on the stock.
- 11/3/2026 – Retension Pharmaceuticals is now covered by Oppenheimer. They set an “outperform” rating and a $50.00 price target on the stock.
- 11/2/2026 – Retension Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $55.00 price target on the stock.
Retension Pharmaceuticals Stock Performance
Shares of Retension Pharmaceuticals stock traded down $0.44 during trading hours on Thursday, hitting $13.45. 28,902 shares of the company’s stock traded hands, compared to its average volume of 121,190. Retension Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $18.64.
Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) last posted its quarterly earnings results on Wednesday, November 18th. The company reported ($7.33) earnings per share (EPS) for the quarter. As a group, analysts predict that Retension Pharmaceuticals, Inc. will post -6.24 EPS for the current fiscal year.
Insider Buying and Selling
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Featured Stories
- Five stocks we like better than Retension Pharmaceuticals
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for Retension Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
